Deltagen (DGEN) Stock Analysis & Winston Score
Deltagen Inc. is a small healthcare company operating in the medical instruments and supplies space. It develops tools and technologies used in biological and medical research, with a focus on gene-function analysis. Its primary customers are research institutions, pharmaceutical companies, and biotechnology firms that need detailed information about how specific genes behave in living organisms. The company generates revenue by licensing its proprietary database of gene knockout mouse models and related research data to customers who pay for access to that information. Deltagen operates primarily in the United States and is a very small company, with a market cap that rounds to essentially zero, limiting its resources compared to larger competitors. Its main competitive edge is its specialized database of genetic research data, which took years to build, but the key risk is that the company is extremely small and may struggle to fund ongoing operations or compete against larger, better-capitalized research tool providers.
Winston Score: 38/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Strong (21/30)
- Growth: Weak (3/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Good (6/10)
- Ownership: Weak (1/15)
Key Facts
Price: $0.00
Market Cap: $0M
Sector: Industrials
Industry: Specialty Business Services


